Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial | Zendy

Ivo W. TremontLukats | Zendy; Bin S. Teh | Zendy

Open Access

Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial

Author(s) -

Ivo W. TremontLukats,

Bin S. Teh

Publication year - 2019

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2019.06.43

Subject(s) - lomustine , temozolomide , o 6 methylguanine dna methyltransferase , nitrosourea , methyltransferase , oncology , glioblastoma , medicine , dna methyltransferase , cancer research , chemotherapy , dna , biology , methylation , vincristine , genetics , cyclophosphamide

The Neuro-Oncology Working Group of the German Cancer Society ( Neuroonkologische Arbeitsgemeinshaft , NOA), studied the effect of lomustine (CCNU, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and temozolomide together to treat patients with newly diagnosed glioblastoma with a methylated O6-methylguanine DNA methyltransferase (MGMT) promoter (1). This strategy needed testing after the encouraging results of a phase II trial (2), and the synergistic or additive effect between temozolomide and lomustine since nitrosoureas have additional non-alkylating effects on DNA and cell replication (3).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research